Theriva Biologics (NYSEAMERICAN:TOVX) Announces Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) posted its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share for the quarter, FiscalAI reports.

Theriva Biologics Price Performance

TOVX stock traded up $0.01 during midday trading on Thursday, reaching $0.24. 411,759 shares of the stock were exchanged, compared to its average volume of 13,684,974. The stock has a market capitalization of $8.27 million, a PE ratio of -0.01 and a beta of 1.11. Theriva Biologics has a 52 week low of $0.16 and a 52 week high of $0.86. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. The company has a fifty day moving average price of $0.24 and a 200 day moving average price of $0.24.

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP acquired a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.